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SUMMARY
Angiotensin receptor blockers (ARBs) have become esta-
blished as a major class of antihypertensive on the basis of
their powerful effects on blood pressure (BP), excellent
tolerability and pleiotropic end-organ-protective effects.
However, individual ARBs vary in antihypertensive effi-
cacy, which may be important to clinical outcome. Several
strategies are available to ensure that BP reductions with
ARBs are at least as great as that which can be achieved
with other antihypertensive classes. Firstly, several newer
ARBs, including irbesartan, candesartan, telmisartan and
olmesartan, have been reported to provide equivalent anti-
hypertensive efficacy to amlodipine and greater efficacy
than either losartan, valsartan or both. Secondly, increases
in dose may improve the antihypertensive efficacy of agents
such as valsartan, although clinical studies are necessary to
provide characterisation of new, higher-dose monothera-
pies. Thirdly, fixed dose combinations with hydrochloro-
thiazide (HCTZ) increase the antihypertensive effect of
all ARBs. It is likely that differences in efficacy between
newer and older ARBs will in some cases be sustained in
combination therapy, such that the most potent ARBs and
HCTZ will provide another tier of control. The future use of
ARBs is likely to involve a growing emphasis on compound-
specific data, with regard to the antihypertensive efficacy and
pleiotropic protective actions of agents.
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INTRODUCTION
Angiotensin receptor blockers (ARBs) are powerful antihyperten-
sives that have rapidly become established as one of the leading
therapeutic classes in the management of hypertension. In addi-
tion to their antihypertensive efficacy, their rapid ascendancy
reflects two cardinal strengths which distinguish these agents
from previous classes of antihypertensive. Firstly, several large
clinical trials have reported that ARBs have pleiotropic effects
that are protective of end-organ function independently of their
effects on blood pressure (BP) (1–6). Secondly, ARBs have excel-
lenttolerability,whichsupportsimprovedpatientpersistencewith
medication and thereby improved long-term BP control (7,8).
During the past year, there has been considerable discus-
sion of the strategies by which aggressive BP control can be
optimised using ARBs. Several newer ARBs have been
reported to reduce BP more effectively than losartan or val-
sartan, while the availability of fixed dose hydrochlorothiazide
(HCTZ) combinations provide further options for optimising
the basic antihypertensive power that can be achieved with
ARB-based therapy. Here, we review the clinical role of the
ARBs in their core indication of BP control and consider the
available strategies for ensuring that the full range of benefits
delivered by these agents – powerful BP reductions, end-
organ protection and good tolerability – are optimised.
AGGRESSIVE BP CONTROL: A CHALLENGE FOR
ANTIHYPERTENSIVES
It is well established that achieving ambitious BP targets
improves long-term clinical outcomes in the management of
hypertension (9–11). In particular, aggressive lowering of
systolic BP (SBP) has been identified as a key goal of anti-
hypertensive therapy (12). The importance of aggressive BP
control with ambitious targets is now entrenched in clinical
guidelines in both the United States and Europe (13,14). The
importance of promptly achieving and then sustaining aggres-
sive BP targets was recently illustrated in the Valsartan
Antihypertensive Long-term Use Evaluation (VALUE) trial,
which evaluated the importance of the long-term treatment of
hypertension with either valsartan or amlodipine, with regard
to cardiovascular events and death (15). A major factor in the
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REVIEW doi: 10.1111/j.1368-5031.2005.00784.xoutcome of VALUE was the superior antihypertensive efficacy
of amlodipine, at the trial dose of 5–10 mg, in comparison
with the valsartan dose of 80–160 mg/day used in this study.
At these doses, amlodipine reduced BP more rapidly than
valsartan during the first 6 months, with a 1–2 mmHg
difference inachieved BP sustained thereafter. Thus, amlodipine’s
greater antihypertensive efficacy appeared to compensate
for its more modest protective effects against end-organ
dysfunction and adverse effects (16).
AGGRESSIVE THERAPY: THE ROLE OF NEWER
ARBs
One potentialapproachtooptimising aggressive antihypertensive
therapy with ARBs is to select a high potency agent and an agent
with the most effective starting dose. Since the introduction of
losartan and valsartan, several newer ARBs have been reported to
reduce BP to a greater degree than these two agents. A meta-
analysis of 51 trials reported diastolic BP (DBP)/SBP reductions
of 8.0/5.5 and 7.5/4.0 mmHg for losartan 50–100 mg and
valsartan 80–160 mg, respectively, compared with 10.0/
6.5 mmHg for irbesartan 150–300 mg, 10.0/6.0 mmHg for
candesartan 8–32 mg and 9.5/6.0 mmHg for telmisartan
20–80 mg (17). Studies such as VALUE underline the import-
ance of these differences in efficacy and the need to achieve timely
and sustained BP targets in the management of hypertension.
Several newer agents have been reported to have equivalent
antihypertensive efficacy to amlodipine at its standard
5–10 mg dose range. In a study of 60 hypertensives with left
ventricular hypertrophy, the antihypertensive efficacy of irbesar-
tan 150–300 mg/day was found to be at least as effective as
amlodipine 5–10 mg/day across the dose range (18), and two
further studies, including the IDNT clinical trial and a short-
term comparison of irbesartan 150 mg and amlodipine 5 mg in
181 patients, also reported comparable antihypertensive efficacy
of irbesartan and amlodipine (5,19). In a study of 251 patients
with mild hypertension, candesartan 16–32 mg daily was
reported to have equivalent antihypertensive efficacy to amlodi-
pine 5–10 mg daily (20). A study in 150 patients with
telmisartan 40–80 mg daily detected no differences in 24-h
BP control with amlodipine 5–10 mg daily (21). Similar BP
control was also reported in a study of 440 patients with mild-
to-moderate hypertension for starting doses of olmesartan
20 mg/day and amlodipine 5 mg/day (22).
Comparisons with Losartan and Valsartan
The differential effects of standard starting doses of irbesartan
150 mg, valsartan 80 mg and losartan 50 mg on the SBP
response to exogenous angiotensin II in 12 healthy normo-
tensive subjects are shown in Figure 1 (23). The irbesartan-
induced blockade was significantly more pronounced than
that achieved by losartan or valsartan for 24 h after dosing,
indicating greater and more sustained AT1 receptor blockade
with irbesartan. This pharmacologic difference needs to be
confirmed by comparative clinical trials.
Greater efficacy compared with losartan has been reported in
the clinical setting for irbesartan and several other newer ARBs.
In a double-blind, placebo-controlled trial involving 567
patients with mild-to-moderate hypertension, irbesartan
300 mg provided superior and more rapid BP control com-
pared with losartan 100 mg (24). Significant differences were
evident as early as the first week – a notable finding in light of
the growing emphasis on rapid BP control. A further study has
confirmed the superior antihypertensive effect and more rapid
control of BP achieved with irbesartan 150–300 mg compared
with losartan 50–100 mg (25). In a 6-week, double-blind,
placebo-controlledstudy in223 patients with mild-to-moderate
hypertension, telmisartan at doses of 40 and 80 mg/day was
found to achieve superior 24-h BP control at 6 weeks to losar-
tan, although losartan was given at a low 50 mg daily dose (26).
In an 8-week study of clinical and ambulatory hypertension in
268 patients, candesartan 8–16 mg/day was reported to reduce
SBP and DBP to a significantly greater degree than losartan
50–100 mg after both 4 and 8 weeks (27). Similar results were
reported in an 8-week study of 332 patients by Gradman et al.
(28). Also, in a 12-week study of 316 patients with mild-to-
moderate hypertension, olmesartan 10–20 mg/day was
reported to reduce BP to a significantly greater degree than
losartan 50 mg/day (29) All ARBs were well tolerated.
There are fewer studies comparing the newer ARBs with
valsartan. However, an 8-week study of 426 patients with
mild-to-moderate hypertension found that irbesartan at its
standard starting dose of 150 mg once daily was associated
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Figure 1 Differential effects of losartan, valsartan and irbesartan
in normotensive subjects. Time course of the in vivo angiotensin II
receptor blockade induced by 50 mg of losartan (e), 80 mg of
valsartan (.), 150 mg of irbesartan (s), and placebo (&). Values are
mean   SEM. *p < 0.05. **p < 0.01 vs placebo. #p < 0.05 vs
other antagonists (Reproduced with permission from Mazzolai L
et al. Hypertension 1999; 33: 850(23)).
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comparable starting dose of 80 mg (30). Mean reductions in
DBP at trough were 6.7 mmHg for irbesartan 150 mg com-
pared with 4.8 mmHg for valsartan 80 mg (p ¼ 0.035),
while mean reductions in SBP at trough were 11.6 mmHg
for irbesartan compared with 7.5 mmHg for valsartan,
respectively (p < 0.01). In addition, significantly more
patients treated with irbesartan achieved normalised BP
(DBP < 90 mmHg; 52.5% vs. 38.2%; p ¼ 0.004). A starting-
dose study of olmesartan 20 mg in essential hypertensives was
reported to have equivalent efficacy to irbesartan 150 mg on
most parameters, but greater efficacy than losartan 50 mg or
valsartan 80 mg (31). After initial studies reported conflicting
results between telmisartan and valsartan (32,33), a combined
analysis of two further studies comparing telmisartan
40–80 mg with valsartan 80–160 mg involving a total of
over 800 patients found significantly greater reductions in
both SBP and DBP at 8 weeks in the telmisartan group (34).
These direct comparisons between ARBs must be evaluated
with care. The studies are of varying size and duration; not all
use like-for-like dosing comparisons and they have been car-
ried out across a range of patient populations with a diversity
of BP measurement techniques and endpoints. Moreover,
subtle aspects of the methodology may in some cases impact
on the reported results. However, it is apparent that at their
current standard doses, four ARBs – irbesartan 150–300 mg,
candesartan 8–32 mg, olmesartan 20–40 mg and telmisartan
40–80 mg – all reduce BP more effectively than losartan
50–100 mg. In addition, irbesartan 150 mg, olmesartan
20 mg and telmisartan 60–80 mg have all been reported to
reduce BP to a greater degree than valsartan at comparable
doses. These agents clearly strengthen the ability of the ARB
class to achieve aggressive BP control with ARB-based therapy.
HIGHER POTENCY OR HIGHER DOSES?
The potency of individual ARBs is a function of pharmaco-
kinetic factors, including bioavailability, volume of distribu-
tion and elimination half-life (35) and differences in the
nature and potency of interaction with the AT1 receptor,
including binding affinity, dissociation and whether the
inhibition is insurmountable or competitive (Table 1) (35–39).
On the basis of elimination half-lives, losartan, valsartan and
eprosartan have been described as shorter-acting agents, with
irbesartan, candesartan and telmisartan described as longer
acting (35); and while candesartan and irbesartan block the
AT1 receptor with maximal antagonism, losartan and valsar-
tan have been classified as competitive antagonists (35).
However, although the newer ARBs have higher potency,
their reported improvements in efficacy may also be a func-
tion of more rational posology. Another option for increasing
the antihypertensive efficacy of the less-potent ARBs may
therefore be to administer them at higher doses. For instance,
in the wake of the VALUE study, it is apparent that the dose
range of 80–160 mg daily that has previously been stated to
be optimal for valsartan is not appropriate for all patients
(40). One issue for the introduction of high monotherapy
doses, however, is the availability of supporting data. The
publication of extensive trials data will be necessary to
characterise in detail the efficacy and tolerability profile of
compounds administered at greater maximum doses than
were typical for their original trials programmes.
COMBINATION THERAPY AND
ANTIHYPERTENSIVE POWER
ARBs have enhanced efficacy when combined with 12.5–
25 mg dose of the diuretic HCTZ, providing an additional
option for tighter BP control. An important question arising
from the availability of fixed dose combination products is
whether the efficacy advantages reported for some of the
newer ARBs compared with valsartan and losartan are
reduced by the addition of HCTZ in the combination ther-
apy. In the case of irbesartan and valsartan, the difference in
efficacy seen in monotherapy (30) appears to be sustained: a
recent 8-week study of prospective, randomised, open-label,
blinded-endpoint design in 414 patients comparing irbesartan
150 mg/HCTZ 12.5 mg with valsartan 80 mg/HCTZ
12.5 mg reported that the irbesartan/HCTZ combination
was associated with greater mean reductions of 2.4 mmHg
(p ¼ 0.0094) and 2.0 mmHg (p ¼ 0.0007), respectively,
in-home SBP and DBP compared with valsartan/HCTZ;
Table 1 Pharmacokinetic and pharmacologic parameters of angiotensin receptor blockers (35–39)
Standard dose range (mg) Half-life (h) Volume of distribution (l) Bioavailability (%) Receptor binding
Losartan 50–100 2 (6–9)* 34 (12)* 33 Competitive (insurmountable)*
Valsartan 80–160 (maximum 320) 6 17 25 Competitive
Irbesartan 150–300 11–15 53–93 60–80 Insurmountable
Candesartan 8–32 9–12 0.13 L/kg 15 Insurmountable
Telmisartan 20–80 24 500 42–58 Insurmountable
Olmesartan 20–40 13 17 26 Insurmountable
Eprosartan 400–800 5–7 13 13 Insurmountable
*EXP 3171 active metabolite of losartan.
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treated with irbesartan had their BP normalised (<135/
85 mmHg; 50.2% vs. 33.2%; p < 0.0001). The overall
safety was similar in the irbesartan/HCTZ and valsartan/
HCTZ groups.
Results for some of the other ARB fixed dose combinations
have been more variable. In a 6-week study involving nearly
400 patients, telmisartan 40 mg or 80 mg plus HCTZ
12.5 mg was found to reduce BP to a significantly greater
degree than losartan/HCTZ 50 mg/12.5 mg (42), but a lar-
ger 6-week study of 682 patients found that telmisartan
80 mg/HCTZ 12.5 mg did not achieve greater reductions
in BP than losartan 50 mg/HCTZ 12.5 mg (43). A study
comparing candesartan/HCTZ 16 mg/12.5 mg with losartan/
HCTZ 50 mg/12.5 mg in 299 patients with mild-to-moderate
hypertension reported significantly greater reductions in the
candesartangroup(44).AlloftheARB fixeddosecombinations
were well tolerated. Further comparative studies are therefore
required, but on the basis of the irbesartan data, it appears that
the combination of the most potent ARBs with high-dose
HCTZprovidestheoption of a furtherlevelof highlyaggressive
BP control for difficult-to-treat patients.
CONCLUSIONS: BALANCING POWER,
PROTECTION AND TOLERABILITY
The first and major objective of antihypertensive therapy is to
achieve effective BP control, using therapy that rapidly
achieves ambitious targets. While this goal is supported by
all ARBs, the ability of the class to achieve them has been
enhanced by the introduction of newer, more potent mol-
ecules such as irbesartan, candesartan and olmesartan, and by
the availability of fixed dose HCTZ combinations for all
agents. Developments in the posology of some of the older
ARBs may further increase the antihypertensive efficacy of
these agents in monotherapy, although these will need to be
supported by detailed clinical characterisation. The availabil-
ity of HCTZ fixed dose combinations provides increased
antihypertensive efficacy for all ARBs, and it is likely that
the differences in antihypertensive efficacy revealed between
some of the newer and older agents in monotherapy will be
sustained in this context, providing an additional level of
control.
The emerging differences among the members of the ARB
class should not obscure the fact that all ARBs are powerful
reducers of BP, and that, as a class, ARBs are unique among
antihypertensives in their very good tolerability. Furthermore,
the end-organ-protective properties of ARBs remain a major
rationale for their use. In this context, major long-term data
on end-organ protection are still lacking for some of the most
recently introduced ARBs. Those agents that will set a bench-
mark for the class are those that provide a strong evidence-
based foundation not for BP-lowering efficacy alone but for
all three goals of antihypertensive therapy – powerful BP
control, end-organ protection and tolerability. It is by provid-
ing patients with this triad of benefits, on a compound-
specific and evidential basis, that the ARBs will continue to
improve standards of clinical hypertension management.
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